Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Weigao Purui for a total transaction amount of 8.511 billion yuan, which will enhance its product line into pharmaceutical packaging materials and expand its market presence in the biopharmaceutical upstream business [1][2]. Group 1: Acquisition Details - The acquisition will be executed through a share issuance priced at 31.29 yuan per share, with approximately 272 million shares to be issued, representing 39.43% of the total share capital post-issuance [1]. - After the transaction, Weigao Blood Purification's controlling shareholder will change from Weigao Group to Weigao Co., which will hold an 84.36% stake, maintaining the actual controller as Chen Xueli [1]. Group 2: Financial Performance of Weigao Purui - Weigao Purui has a strong market position, holding over 50% of the domestic market share for pre-filled products from 2022 to 2024, ranking first in the industry [2]. - The company has demonstrated robust profitability, with projected revenues of 1.426 billion yuan, 1.684 billion yuan, and 939 million yuan for 2023 to the first half of 2025, and net profits of 490 million yuan, 585 million yuan, and 327 million yuan for the same periods [2]. Group 3: Weigao Blood Purification's Business Overview - Weigao Blood Purification is a leading enterprise in the blood purification field, focusing on the R&D and production of blood dialysis devices and related products [2]. - The company has shown steady performance, with total revenue of 2.736 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 3.45%, and a net profit of 341 million yuan, up 7.92%, with a gross margin of 40.69% [2]. Group 4: Future Projections - Following the acquisition, Weigao Blood Purification's profitability is expected to improve significantly, with projected increases in revenue and net profit of 51.56% and 142.57%, respectively, for the first three quarters of 2025, and total assets anticipated to reach 12.044 billion yuan [2].
作价超85亿元，威高血净“拿下”威高普瑞